Clinical Trial Update: Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of ivosidenib for patients with clonal cytopenia of undetermined significance (CCUS) due to IDH1 mutations; the study is sponsored…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clonal Cytopenia of Undetermined Significance

Drugs mentioned

• Ivosidenib (ivosidenib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Clonal Cytopenia of Undetermined Significance | Phase 2 | Status: ACTIVE_NOT_RECRUITING